* U.S. Launch targeted for April 2010
* Shares up 61 percent in pre-market trade
March 10 (Reuters) - Oculus Innovative Sciences Inc OCLS.O said its Microcyn Skin and Wound HydroGel was approved by U.S. health regulators, sending its shares up 61 percent before the bell.
The company said the product, intended for management of wounds, including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue, will be commercially available in April.
Shares of Oculus were trading at $2.89 before the bell. They had closed at $1.81 Tuesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Bijoy Koyitty)